Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation - TripCo Outstanding Awards (Details)

v3.21.2
Stock-Based Compensation - TripCo Outstanding Awards (Details) - 2019 Plan
$ / shares in Units, shares in Thousands, $ in Millions
6 Months Ended
Jun. 30, 2021
USD ($)
$ / shares
shares
Additional disclosures  
Unvested value not yet recognized | $ $ 7.1
Weighted average period the unrecognized compensation cost will be recognized 2 years 4 months 24 days
Amount of share reserve 3,500
Stock Options | Series A  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Outstanding beginning balance 1,086
Granted 53
Forfeited/Cancelled (1)
Outstanding ending balance 1,138
Options exercisable 366
WAEP  
Weighted average exercise price, options outstanding (in dollars per share) | $ / shares $ 7.78
Weighted average exercise price, options granted (in dollars per share) | $ / shares 5.65
Weighted average exercise price, options forfeited/cancelled (in dollars per share) | $ / shares 35.05
Weighted average exercise price, options outstanding (in dollars per share) | $ / shares 7.67
Weighted average exercise price, options exercisable (in dollars per share) | $ / shares $ 14.33
Weighted average remaining contractual term outstanding 5 years 4 months 24 days
Weighted average remaining contractual term exercisable 3 years 6 months
Stock Options | Series B  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Outstanding beginning balance 2,397
Outstanding ending balance 2,397
Options exercisable 2,397
WAEP  
Weighted average exercise price, options outstanding (in dollars per share) | $ / shares $ 21.93
Weighted average exercise price, options outstanding (in dollars per share) | $ / shares 21.93
Weighted average exercise price, options exercisable (in dollars per share) | $ / shares $ 21.93
Weighted average remaining contractual term outstanding 4 years 2 months 12 days
Weighted average remaining contractual term exercisable 4 years 2 months 12 days
Outstanding, aggregate intrinsic value | $ $ 25.0
Exercisable, aggregate intrinsic value | $ $ 25.0
Performance Based RSUs | Series B | CEO  
Additional disclosures  
RSUs granted 154
Weighted average grant date fair value, RSUs and MSUs granted (in dollars per share) | $ / shares $ 7.07
Vesting period 1 year